Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer

International Journal of Urology

Volumn 23, Issue 5, 2016, Pages 360-369

  Shiota, Masaki ^a   Eto, Masatoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Abiraterone acetate; Androgen deprivation therapy; Enzalutamide; Hormone sensitive prostate cancer; Taxane

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; APALUTAMIDE; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METFORMIN; ORTERONEL; PLACEBO; RADIOPHARMACEUTICAL AGENT; RADIUM 223; TUMOR MARKER; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; TAXOID;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; CASTRATION; HUMAN; INTERMETHOD COMPARISON; MEDICAL CASTRATION; METASTATIC HORMONE SENSITIVE PROSTATE CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SURGICAL CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DISEASE EXACERBATION; MALE;

ANDROGEN ANTAGONISTS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84963860981     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.13091     Document Type: Review

References (110)

1. Davison SL, Bell R. Androgen physiology. Semin. Reprod. Med. 2006; 24: 71-7.
2. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68: 4447-54.
3. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994; 63: 25-61.
4. Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006; 231: 12-9.
5. Shiota M, Yokomizo A, Fujimoto N, Naito S. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Curr. Cancer Drug Targets 2011; 11: 870-81.
6. Shiota M, Yokomizo A, Naito S. Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr. Relat. Cancer 2012; 19: R243-53.
7. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-7.
8. Saad F, Fizazi K. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer. Urology 2015; 86: 852-61.
9. Rhee H, Gunter JH, Heathcote P et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015; 115: 3-13.
10. Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S. Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration. Curr. Cancer Drug Targets 2013; 13: 444-59.
11. Fujimoto N. Novel agents for castration-resistant prostate cancer: early experience and beyond. Int. J. Urol. 2016; 23: 114-21.
12. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 2007; 25: 1596-605.
13. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2014; 65: 467-79.
14. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016; 117: 102-9.
15. Shahinian VB, Kuo YF. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer. BMC Urol. 2015; 15: 25.
16. Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J. Urol. 2003; 170: 1703-8.
17. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J. Urol. 1986; 135: 303-7.
18. Schally AV, Arimura A, Baba Y et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem. Biophys. Res. Commun. 1971; 43: 393-9.
19. Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991; 1: 487-509.
20. Fujino M, Fukuda T, Shinagawa S, Kobayashi S, Yamazaki I. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem. Biophys. Res. Commun. 1974; 60: 406-13.
21. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med. 1984; 311: 1281-6.
22. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. 2000; 132: 566-77.
23. Sarosdy MF, Schellhammer PF, Sharifi R et al. Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology 1998; 52: 82-8.
24. Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br. Med. J. 1985; 291: 1387-8.
25. Kuhn JM, Billebaud T, Navratil H et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 1989; 321: 413-8.
26. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 2010; 75: 642-7.
27. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102: 1531-8.
28. Crawford ED, Shore ND, Moul JW et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014; 83: 1122-8.
29. Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J. Urol. 2003; 170: S48-52.
30. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J. Clin. Oncol. 2004; 22: 2546-53.
31. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J. Urol. 2004; 171: 2272-6.
32. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur. Urol. 2007; 51: 306-13.
33. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur. Urol. 2006; 49: 54-8.
34. Morote J, Esquena S, Abascal JM et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol. Int. 2006; 77: 135-8.
35. van der Sluis TM, Bui HN, Meuleman EJ et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J. Urol. 2012; 187: 1601-6.
36. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2006; 24: 4448-56.
37. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur. Urol. 2014; 65: 704-9.
38. Sun M, Choueiri TK, Hamnvik OR et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol. 2015; doi:10.1001/jamaoncol.2015.4917.
39. Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 2010; 57: 836-42.
40. Klotz L, Miller K, Crawford ED et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur. Urol. 2014; 66: 1101-8.
41. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur. Urol. 2014; 65: 565-73.
42. Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J. Clin. Oncol. 1996; 14: 2250-7.
43. Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand. J. Urol. Nephrol. 1996; 30: 93-8.
44. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46: 849-55.
45. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of "Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. 1998; 33: 447-56.
46. Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne F. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur. Urol. 1995; 28: 215-22.
47. Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-96.
48. Boccon-Gibod L, Fournier G, Bottet P et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur. Urol. 1997; 32: 391-5.
49. Kunath F, Grobe HR, Rücker G et al. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. BJU Int. 2015; 116: 30-6.
50. Labrie F, Dupont A, Belanger A et al. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Horm. Res. 1983; 18: 18-27.
51. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989; 321: 419-24.
52. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998; 339: 1036-42.
53. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst. Rev. 2000; 2: CD001526.
54. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8.
55. Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-76.
56. Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997; 50: 330-6.
57. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004; 93: 1177-82.
58. Akaza H, Hinotsu S, Usami M et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437-45.
59. Kirk D. Timing and choice of androgen ablation. Prostate Cancer Prostatic Dis. 2004; 7: 217-22.
60. Studer UE, Hauri D, Hanselmann S et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J. Clin. Oncol. 2004; 22: 4109-18.
61. Studer UE, Whelan P, Wimpissinger F et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Eur. Urol. 2014; 66: 829-38.
62. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993; 71: 2782-90.
63. Sato N, Gleave ME, Bruchovsky N et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J. Steroid Biochem. Mol. Biol. 1996; 58: 139-46.
64. Hussain M, Tangen CM, Berry DL et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 2013; 368: 1314-25.
65. Magnan S, Zarychanski R, Pilote L et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2015; 1: 1261-9.
66. Hershman DL, Unger JM, Wright JD et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2015; doi:10.1001/jamaoncol.2015.4655.
67. Gleave M. Prime time for intermittent androgen suppression. Eur. Urol. 2014; 66: 240-2.
68. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-12.
69. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513-20.
70. Eigl BJ, Eggener SE, Baybik J et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin. Cancer Res. 2005; 11: 4905-11.
71. Shiota M, Kashiwagi E, Yokomizo A et al. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor. Prostate 2013; 73: 1336-44.
72. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14: 149-58.
73. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-46.
74. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2015; doi:10.1016/S0140-6736(15)01037-5.
75. Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra Ann. Oncol. 2015; 26: 1660-7.
76. Tucci M, Bertaglia V, Vignani F et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur. Urol. 2015; doi:10.1016/j.eururo.2015.09.013.
77. Shiota M, Yokomizo A, Eto M. Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy. Front. Oncol. 2016; 5: 304.
78. Vale CL, Burdett S, Rydzewska LH et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016; 17: 243-56.
79. National Comprehensive Cancer Network. NCCN Guidelines. Available from URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
80. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
81. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 2004; 10: 7121-6.
82. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012; 367: 1187-97.
83. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014; 371: 424-33.
84. Tombal B, Borre M, Rathenborg P et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014; 15: 592-600.
85. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012; 72: 1494-503.
86. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011; 364: 1995-2005.
87. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 2013; 368: 138-48.
88. Saad F, Fizazi K, Jinga V et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015; 16: 338-48.
89. Fizazi K, Jones R, Oudard S et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J. Clin. Oncol. 2015; 33: 723-31.
90. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin. Oncol. 2005; 23: 7897-903.
91. Krupski TL, Smith MR, Lee WC et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101: 541-9.
92. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 2005; 352: 154-64.
93. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 2003; 169: 2008-12.
94. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann. Intern. Med. 2007; 146: 416-24.
95. Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur. Urol. 2013; 63: 927-35.
96. Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2009; 361: 745-55.
97. Smith MR, Saad F, Egerdie B et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 2009; 182: 2670-5.
98. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 2004; 96: 879-82.
99. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
100. Smith MR, Halabi S, Ryan CJ et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J. Clin. Oncol. 2014; 32: 1143-50.
101. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013; 369: 213-23.
102. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014; 15: 738-46.
103. Hoskin P, Sartor O, O'Sullivan JM et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014; 15: 1397-406.
104. Yu EY, Li H, Higano CS et al. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 2015; 33: 1601-8.
105. Smith MR, de BJ, Sternberg CN et al. Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J. Clin. Oncol. 2015; 33 (Suppl 7): abstr 139.
106. Basch EM, Scholz MC, de BJ et al. Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J. Clin. Oncol. 2015; 33 (Suppl 7): Abstr 141.
107. Shiota M, Yokomizo A, Tada Y et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010; 29: 237-50.
108. Shiota M, Yokomizo A, Naito S. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Free Radic. Biol. Med. 2011; 51: 1320-8.
109. Shiota M, Song Y, Takeuchi A et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J. Urol. 2012; 187: 707-14.
110. Thomas R, Sharifi N. SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer. Mol. Cancer Ther. 2012; 11: 87-97.